Skip to content
★ Sign in to follow
VV

Vlad Vitoc

CEO
Chief Executive Officer
Insider activity · 24 months5 buys0 salesCumulative net flow
Total declarations
20
Company
1
▲ Purchases (20 ops.)
€268k
▼ Sales (0 ops.)
—

Latest filing published 15 Sept 2026 for MAIA Biotechnology, Inc., €86k.

Filing timeline

BuySale
Vlad Vitoc

Insider track record

Disclosed buys
20
Disclosed sells
0
Signal history

Closed purchases

Market purchases
20
Positive at T+90
29%
Median T+90
-33.4%

Based on 14 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.

Purchases by company

Since each purchase

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Vlad Vitoc: trading record in brief

All filings by Vlad Vitoc on record concern MAIA Biotechnology, Inc., in the capacity of chief executive. We count 20 filings; the first trade dates from 1 August 2022 and the latest from 14 September 2026.

The open-market record is one-sided, with 20 purchases worth €268k and not one sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Since January 2026: 1 purchase and no sales on the market.

A typical purchase (the median) is worth €4,906. Measured against the company's value, the median purchase equals 0.026% of market capitalisation, across 3 purchases where it is known. 17 out of 18 purchases came within 30 days of a purchase by at least one other insider of the same company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. Ninety days after publication, 14 purchases show a median change of -33.4%, with the price up in 29% of them. Past outcomes like these are no guarantee of what comes next.

The latest filing, published on 15 September 2026, reports an open-market purchase of €86k in MAIA Biotechnology, Inc. Typically, a trade is published a median of 3 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.

Companies and markets linked to Vlad Vitoc

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations18 total
  • ▲
    Chief Executive OfficerExecutivesMAIA Biotechnology, Inc.
    100,010 USD56SEC
    73,000 shares@ US$1.370.12% mcap37.5% of flowCommon StockSEC:0001878313-26-000087:0
    Canonical exit: 13 Dec 2026 (T+90)
  • ▲
    Chief Executive OfficerExecutivesMAIA Biotechnology, Inc.
    23,019 USD42SEC
    22,000 shares@ US$1.04630.026% mcap8.6% of flowCommon StockSEC:0001878313-25-000059:0
    Canonical exit: 24 Feb 2026 (T+90)
  • ▲
    Chief Executive OfficerExecutivesMAIA Biotechnology, Inc.
    56,830 USD45SEC
    50,000 shares@ US$1.136621.3% of flowCommon StockSEC:0001878313-25-000056:0
    Canonical exit: 26 Feb 2026 (T+90)
  • ▲
    Chief Executive OfficerExecutivesMAIA Biotechnology, Inc.
    10,144 USD39SEC
    10,500 shares@ US$0.96613.8% of flowCommon StockSEC:0001878313-25-000047:0
    Canonical exit: 23 Feb 2026 (T+90)
  • ▲
    Chief Executive OfficerExecutivesMAIA Biotechnology, Inc.
    1,656 USD22SEC
    1,800 shares@ US$0.920.6% of flowCommon StockSEC:0001878313-25-000040:0
    Canonical exit: 19 Feb 2026 (T+90)
  • ▲
    Chief Executive OfficerExecutivesMAIA Biotechnology, Inc.
    10,000 USD46SEC
    4,000 shares@ US$2.503.9% of flowCommon StockSEC:0001127602-23-013819:0
    Canonical exit: 27 Jul 2023 (T+90)
  • ▲
    Chief Executive OfficerExecutivesMAIA Biotechnology, Inc.
    4,813 USD46SEC
    1,375 shares@ US$3.501.9% of flowCommon StockSEC:0001127602-23-012463:0
    Canonical exit: 2 Jul 2023 (T+90)
  • ▲
    Chief Executive OfficerExecutivesMAIA Biotechnology, Inc.
    703 USD46SEC
    205 shares@ US$3.430.3% of flowCommon StockSEC:0001127602-23-011737:0
    Canonical exit: 28 Jun 2023 (T+90)
  • ▲
    Chief Executive OfficerExecutivesMAIA Biotechnology, Inc.
    6,656 USD46SEC
    1,581 shares@ US$4.212.7% of flowCommon StockSEC:0001127602-23-009532:0
    Canonical exit: 6 Jun 2023 (T+90)
  • ▲
    Chief Executive OfficerExecutivesMAIA Biotechnology, Inc.
    2,307 USD46SEC
    544 shares@ US$4.240.9% of flowCommon StockSEC:0001127602-23-009392:0
    Canonical exit: 4 Jun 2023 (T+90)
  • ▲
    Chief Executive OfficerExecutivesMAIA Biotechnology, Inc.
    199 USD46SEC
    45 shares@ US$4.420.1% of flowCommon StockSEC:0001127602-23-008972:0
    Canonical exit: 31 May 2023 (T+90)
  • ▲
    Chief Executive OfficerExecutivesMAIA Biotechnology, Inc.
    5,725 USD46SEC
    1,275 shares@ US$4.492.3% of flowCommon StockSEC:0001127602-23-008066:0
    Canonical exit: 29 May 2023 (T+90)
  • ▲
    Chief Executive OfficerExecutivesMAIA Biotechnology, Inc.
    310 USD46SEC
    73 shares@ US$4.250.1% of flowCommon StockSEC:0001127602-23-006340:0
    Canonical exit: 18 May 2023 (T+90)
  • ▲
    Chief Executive OfficerExecutivesMAIA Biotechnology, Inc.
    43 USD43SEC
    10 shares@ US$4.250.0% of flowCommon StockSEC:0001127602-23-005727:0
    Canonical exit: 16 May 2023 (T+90)
  • ▲
    Chief Executive OfficerExecutivesMAIA Biotechnology, Inc.
    1,454 USD43SEC
    343 shares@ US$4.240.6% of flowCommon StockSEC:0001127602-23-005033:0
    Canonical exit: 11 May 2023 (T+90)
  • ▲
    Chief Executive OfficerExecutivesMAIA Biotechnology, Inc.
    4,659 USD38SEC
    1,266 shares@ US$3.681.9% of flowCommon StockSEC:0001127602-23-001010:0
    Canonical exit: 4 Apr 2023 (T+90)
  • ▲
    Chief Executive OfficerExecutivesMAIA Biotechnology, Inc.
    1,435 USD36SEC
    410 shares@ US$3.500.6% of flowCommon StockSEC:0001127602-23-000224:0
    Canonical exit: 30 Mar 2023 (T+90)
  • ▲
    Chief Executive OfficerExecutivesMAIA Biotechnology, Inc.
    30,000 USD41SEC
    6,000 shares@ US$5.0012.7% of flowCommon StockSEC:0000899243-22-027454:0
    Canonical exit: 30 Oct 2022 (T+90)

18 of 18 declarations